An tOrd Gnó - Order of Business
Dail Éireann — 2026-06-16
============================================================

Micheál Martin (FF), Cork South-Central

There are three points. First, we are acutely aware of the pressures and anxieties in families in relation to a number of drugs pertaining to rare diseases. There was good news last week in terms of the HSE drug group approving givinostat and sending it forward to the senior leadership group, which will now consider it. Hopefully we can get this progressed as quickly as possible. There are other drugs. Skyclarys is on the agenda, among others. In fact, we are increasing the number of approvals on a year-by-year basis. The recent pharmaceutical agreement arrived at with the Irish Pharmaceutical Healthcare Association, IPHA, and the Government provides for better timelines in terms of getting drugs approved.
The Minister has also signed off on a review, which, I think, is very important, but only made that decision following work up from her Department officials who have given considerable thought to this because what we will see now and into the future is a greater volume of what used be called orphan drugs for rare diseases. Where companies in the past never invested, now they are. That is going to come at us fairly significantly.

---

Source: Houses of the Oireachtas. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The Official Report is revised after first publication; the fetch timestamp below identifies the version quoted.

Record URI: https://data.oireachtas.ie/akn/ie/debateRecord/dail/2026-06-16/debate/main
Retrieved: 2026-08-27T06:54:50+00:00
Sitting date: 2026-06-16